Major Response to Cyclophosphamide and Prednisone in Recurrent Castration-Resistant Prostate Cancer

Restricted access

Prostate cancer is the most common noncutaneous cancer among men. This case report describes a 43-year-old man with rapidly progressing castration-resistant prostate cancer (CRPC) that responded initially to docetaxel and did not tolerate cabazitaxel. He subsequently received a third line of chemotherapy with cyclophosphamide and prednisone, and experienced a dramatic clinical and radiographic response in his liver metastases. This therapeutic intervention led to a significant clinical benefit and confirms the potential use of cyclophosphamide in patients with CRPC, particularly those with liver metastases.

Correspondence: Roberto Pili, MD, Genitourinary Program, Roswell Park Cancer Institute, Elm and Carlton St, Buffalo, NY 14263. E-mail: Roberto.Pili@RoswellPark.org

Supplementary Materials

    • Supplemental Material (PDF 662 KB)
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 443 379 53
PDF Downloads 39 21 7
EPUB Downloads 0 0 0